EP1789390A2 — Pyridyl inhibitors of hedgehog signalling
Assigned to Genentech Inc · Expires 2007-05-30 · 19y expired
What this patent protects
The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y, R<SUB>1</SUB>, R<SUB>2</SUB>, R<SUB>3</SUB>, R<S…
USPTO Abstract
The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y, R<SUB>1</SUB>, R<SUB>2</SUB>, R<SUB>3</SUB>, R<SUB>4</SUB>, and n are as described herein.
Drugs covered by this patent
- Erivedge (vismodegib) · Roche
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.